Literature DB >> 11292216

Use of botulinum toxin type A in pediatric patients with cerebral palsy: a three-center retrospective chart review.

M E Gormley1, D Gaebler-Spira, M R Delgado.   

Abstract

Over the last several years, botulinum toxin type A has gained widespread use for the management of focal spasticity in children with cerebral palsy. To assess the current patterns of botulinum toxin type A use in the clinical setting, the dose, muscles injected, age at injection, and interval between injections of botulinum toxin type A treatments were examined in a retrospective chart review of children with cerebral palsy (N = 270) over a 2-year period at three major treatment centers. The average dose of botulinum toxin type A across the three centers ranged from 7.7 to 10.8 U/kg body weight, and the average total amount of botulinum toxin type A injected at a single visit ranged from 154 to 205 U. The majority of botulinum toxin type A injections were to the muscles to the lower limbs. The average age at first injection was 6.2 years, and the average interval between injections ranged from 134 to 199 days.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11292216     DOI: 10.1177/088307380101600209

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  10 in total

Review 1.  Systemic weakness after therapeutic injections of botulinum toxin a: a case series and review of the literature.

Authors:  Beth E Crowner; Diego Torres-Russotto; Alexandre R Carter; Brad A Racette
Journal:  Clin Neuropharmacol       Date:  2010 Sep-Oct       Impact factor: 1.592

Review 2.  Botulinum toxin in children with cerebral palsy.

Authors:  Pratibha Singhi; Munni Ray
Journal:  Indian J Pediatr       Date:  2004-12       Impact factor: 1.967

Review 3.  Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin.

Authors:  L Andrew Koman; Beth Paterson Smith; Rajesh Balkrishnan
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 4.  Nonoperative management of spasticity in children.

Authors:  Susan Ronan; Joan T Gold
Journal:  Childs Nerv Syst       Date:  2007-07-24       Impact factor: 1.475

5.  Associations Between Muscle Synergies and Treatment Outcomes in Cerebral Palsy Are Robust Across Clinical Centers.

Authors:  Benjamin R Shuman; Marije Goudriaan; Kaat Desloovere; Michael H Schwartz; Katherine M Steele
Journal:  Arch Phys Med Rehabil       Date:  2018-04-10       Impact factor: 3.966

6.  Long-term effect of repeated injections of botulinum toxin in children with cerebral palsy: a prospective study.

Authors:  Aviva Fattal-Valevski; Dafna Domenievitz; Nir Giladi; Shlomo Wientroub; Shlomo Hayek
Journal:  J Child Orthop       Date:  2008-01-23       Impact factor: 1.548

7.  Neurogenic hip dislocation in cerebral palsy: quality of life and results after hip reconstruction.

Authors:  Alexander Krebs; Walter M Strobl; Franz Grill
Journal:  J Child Orthop       Date:  2008-02-13       Impact factor: 1.548

Review 8.  Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy.

Authors:  Francesco C Blumetti; João Carlos Belloti; Marcel Js Tamaoki; José A Pinto
Journal:  Cochrane Database Syst Rev       Date:  2019-10-08

9.  Therapeutic use of botulinum toxin in neurorehabilitation.

Authors:  Domenico Intiso
Journal:  J Toxicol       Date:  2011-09-14

Review 10.  Botulinum toxin type A injection for management of upper limb spasticity in children with cerebral palsy: a literature review.

Authors:  Eun Sook Park; Dong-Wook Rha
Journal:  Yonsei Med J       Date:  2006-10-31       Impact factor: 2.759

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.